扩展耐药基因 panel 预测血培养革兰阴性菌药敏结果评估
该研究分两阶段评估 QIAstat-Dx BCID Panel(RUO)检测 13 种革兰阴性菌及 18 组耐药基因的性能。阶段 1 用 154 株挑战菌株与全基因组测序比对,菌种鉴定灵敏度 99.3%、特异度 99.8%,耐药基因灵敏度 99.8%、特异度 99.9%。阶段 2 用 101 株临床血培养革兰阴性杆菌分离株,以微量肉汤稀释法为参考,评估鉴定联合耐药基因预测药敏的阴性预测值。
要点
- 挑战菌株中菌种鉴定灵敏度 153/154(99.3%),特异度 1,748/1,749(99.8%)。
- 耐药基因检测灵敏度 434/435(99.8%),特异度 2,334/2,337(99.9%)。
- 临床分离株中联合耐药基因预测药敏的阴性预测值高于现行标准。
核心结论
- 扩展 β-内酰胺酶基因检测对血培养革兰阴性菌药敏预测有附加价值。
研究设计与样本
- 研究分两阶段:阶段 1 用 154 株挑战菌株与全基因组测序比对分析性能。
- 阶段 2 用 101 株临床血培养革兰阴性杆菌分离株,以多重 PCR 与参考微量肉汤稀释法比较。
主要发现
- 阶段 1 菌种鉴定灵敏度 153/154(99.3%),特异度 1,748/1,749(99.8%)。
- 阶段 1 耐药基因灵敏度 434/435(99.8%),特异度 2,334/2,337(99.9%)。
- 挑战集中出现 1 例 blaIMP 假阴性、1 例 blaCTX-M 假阳性和 2 例 aac-6'-Ib 假阳性。
- 阶段 2 阴性预测值:氨苄西林耐药 92.8%(大肠埃希菌 100%)、头孢曲松 93.4%、头孢他啶 97.4%、头孢吡肟 98.7%。
- 现行标准(鉴定加 blaCTX-M 检测)的阴性预测值范围为 56.5% 至 88.8%。
关键数值与推荐
- QIAstat-Dx BCID Panel(RUO)可鉴定 13 种革兰阴性菌和 18 组耐药基因。
- 阶段 2 评估 17 个耐药基因检测对药敏预测的价值。
临床怎么用
- 该多重 PCR 联合耐药基因检测可辅助预测血培养革兰阴性菌的药敏结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The QIAstat-Dx BCID Panels (RUO) ("QIAstat," QIAGEN, Hilden, Germany) for identification of 13 Gram-negative bacteria and 18 antimicrobial resistance (AMR) gene groups was evaluated. The study was conducted in two phases; in phase 1, analytical performance was evaluated against 154 challenge isolates against whole genome sequencing data. In this phase, sensitivity and specificity of organism identification calls were 153/154 (99.3%) and 1,748/1,749 (99.8%), respectively. For AMR genes, sensitivity was 434/435 (99.8%) and specificity was 2,334/2,337 (99.9%). One false-negative blaIMP, one false-positive blaCTX-M, and two false-positive aac-6'-lb detections were noted in this challenge set of organisms. In phase 2, 101 clinical blood culture isolates of Gram-negative rods were evaluated by the multiplexed PCR versus reference broth microdilution, for the ability of identification combined with AMR genes to predict final susceptibility results. Negative predictive values were 92.8% for ampicillin resistance (100% for Escherichia coli), 93.4% for ceftriaxone, 97.4% for ceftazidime, and 98.7% for cefepime. In constrast, negative predictive values for current standard of care (identification plus detection of blaCTX-M) ranged from 56.5% to 88.8%. This study demonstrated additive value of additional beta-lactamase genes for bacteria isolated from blood cultures. IMPORTANCE: Prediction of Gram-negative bacteria resistance through detection of resistance genes is complex. This study evaluated a novel, direct-from-blood or bacterial isolate multiplexed PCR for the detection of 17 resistance genes, and evaluated the prediction of antimicrobial susceptibility.
引用
- Manuel C, Maynard R, Simpkins S, et al. Evaluation of an expanded antibiotic resistance gene panel on prediction of antimicrobial susceptibility results for Gram-negative bacteria in blood cultures. J Clin Microbiol. 2024. PMID: 39297627. doi:10.1128/jcm.01020-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。